Audrey Sternberg


Dose-escalated RT plus androgen suppression yields mixed outcomes in prostate cancer

October 28, 2021

“Patients with intermediate-risk prostate cancer we know benefit from both escalation of radiotherapy dose as well as from the addition of androgen suppression. Technically, we still don’t know if we need both,” said Daniel Krauss, MD.